We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alexion's (ALXN) Soliris' Label Expansion Approved in Europe
Read MoreHide Full Article
Alexion Pharmaceuticals, Inc. announced that the European Commission (EC) approved a label expansion of lead drug Soliris.
The European Commission expanded the indication for Soliris to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive.
We note that Soliris is approved for two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system – paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
In order to increase the commercial potential of the drug further, Alexion is working on expanding Soliris’ label into additional indications. Alexion has aslo filed regulatory application to the FDA for expanding the use of Soliris for the treatment of refractory gMG in patients who are anti-acetylcholine receptor antibody-positive. The FDA accepted the supplemental Biologics License Application (sBLA) and set a Prescription Drug User Fee Act (PDUFA) date of Oct 23.
A potential label expansion in the U.S. will boost sales further. Soliris will be launched for this new indication initially in Germany while Alexion is evaluating launches in additional EU countries.
Alexion’s stock price has increased 9.1%, outperforming the industry’s gain of 5.3%.
Additionally, a phase III study (PREVENT) on Soliris in patients with relapsing neuromyelitis optica spectrum disorder is ongoing with enrolment being expected to be completed in 2017 and data expected in 2018. Label expansion into additional indications will give Soliris access to a higher patient population and increase the commercial potential of the drug significantly.
We note that Soliris has received Orphan Drug Designation (ODD) for the treatment of patients with MG in the U.S. and EU, and for the treatment of patients with refractory gMG in Japan.
We expect growth at Alexion to continue being driven by Soliris. Other new products – Strensiq and Kanuma – are doing well and are expected to boost revenues. However, Soliris quarter-to-quarter revenue growth ($70 million - $100 million) will be impacted by the enrolment ramp-up of trials.
The company is expecting Soliris revenues to be lower in the second half of the year due to an accelerating impact from the ALXN1210 trials. In addition, pricing will impact sales by 1%.
Zacks Rank & Stocks to Consider
Alexion currently carries a Zacks Rank #1 (Strong Buy).
Other top-ranked stocks worth considering in the healthcare sector include Regeneron Pharmaceuticals, Inc. (REGN - Free Report) , Gilead Sciences, Inc. (GILD - Free Report) and Aduro Biotech, Inc. . While Regeneron sport a Zacks Rank #1, Gilead Sciences and Aduro carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Regeneron’s earnings per share estimates have increased from $10.52 to $13.81 for 2017 and from $12.10 to $14.54 for 2018 over the last 30 days. The company pulled off positive earnings surprises in two of the trailing four quarters, with an average beat of 6.29%.
Gilead’s earnings per share estimates increased from $7.98 to $8.53 for 2017, over the last 30 days. The company delivered positive earnings surprises in three of the trailing four quarters, with an average beat of 8.18%.
Aduro Biotech’s loss per share estimates narrowed from $1.46 to $1.32 for 2017 and from $1.41 to $1.24 over the last 30 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.
Zacks' 10-Minute Stock-Picking Secret
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.
Image: Bigstock
Alexion's (ALXN) Soliris' Label Expansion Approved in Europe
Alexion Pharmaceuticals, Inc. announced that the European Commission (EC) approved a label expansion of lead drug Soliris.
The European Commission expanded the indication for Soliris to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive.
We note that Soliris is approved for two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system – paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
In order to increase the commercial potential of the drug further, Alexion is working on expanding Soliris’ label into additional indications. Alexion has aslo filed regulatory application to the FDA for expanding the use of Soliris for the treatment of refractory gMG in patients who are anti-acetylcholine receptor antibody-positive. The FDA accepted the supplemental Biologics License Application (sBLA) and set a Prescription Drug User Fee Act (PDUFA) date of Oct 23.
A potential label expansion in the U.S. will boost sales further. Soliris will be launched for this new indication initially in Germany while Alexion is evaluating launches in additional EU countries.
Alexion’s stock price has increased 9.1%, outperforming the industry’s gain of 5.3%.
Additionally, a phase III study (PREVENT) on Soliris in patients with relapsing neuromyelitis optica spectrum disorder is ongoing with enrolment being expected to be completed in 2017 and data expected in 2018. Label expansion into additional indications will give Soliris access to a higher patient population and increase the commercial potential of the drug significantly.
We note that Soliris has received Orphan Drug Designation (ODD) for the treatment of patients with MG in the U.S. and EU, and for the treatment of patients with refractory gMG in Japan.
We expect growth at Alexion to continue being driven by Soliris. Other new products – Strensiq and Kanuma – are doing well and are expected to boost revenues. However, Soliris quarter-to-quarter revenue growth ($70 million - $100 million) will be impacted by the enrolment ramp-up of trials.
The company is expecting Soliris revenues to be lower in the second half of the year due to an accelerating impact from the ALXN1210 trials. In addition, pricing will impact sales by 1%.
Zacks Rank & Stocks to Consider
Alexion currently carries a Zacks Rank #1 (Strong Buy).
Other top-ranked stocks worth considering in the healthcare sector include Regeneron Pharmaceuticals, Inc. (REGN - Free Report) , Gilead Sciences, Inc. (GILD - Free Report) and Aduro Biotech, Inc. . While Regeneron sport a Zacks Rank #1, Gilead Sciences and Aduro carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Regeneron’s earnings per share estimates have increased from $10.52 to $13.81 for 2017 and from $12.10 to $14.54 for 2018 over the last 30 days. The company pulled off positive earnings surprises in two of the trailing four quarters, with an average beat of 6.29%.
Gilead’s earnings per share estimates increased from $7.98 to $8.53 for 2017, over the last 30 days. The company delivered positive earnings surprises in three of the trailing four quarters, with an average beat of 8.18%.
Aduro Biotech’s loss per share estimates narrowed from $1.46 to $1.32 for 2017 and from $1.41 to $1.24 over the last 30 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.
Zacks' 10-Minute Stock-Picking Secret
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.
Learn the secret >>